# A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes

> **NCT06945406** · PHASE1 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 124 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** LY4057996 SC
- **DRUG:** LY4057996 IV
- **DRUG:** Placebo SC
- **DRUG:** Placebo IV
- **DRUG:** Degludec SC
- **DRUG:** Lispro SC
- **DRUG:** Degludec IV
- **DRUG:** Pre-study basal insulin SC

## Key facts

- **NCT ID:** NCT06945406
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-16
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06945406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06945406, "A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06945406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*